<DOC>
	<DOCNO>NCT00144417</DOCNO>
	<brief_summary>This double-blind , randomize control trial evaluate moxifloxacin versus isoniazid daily treatment first two month treatment rifampin , pyrazinamide ethambutol sputum smear-positive pulmonary tuberculosis .</brief_summary>
	<brief_title>TBTC Study 28 : Moxifloxacin Versus Isoniazid TB Treatment</brief_title>
	<detailed_description>The primary objective Phase 2 clinical trial compare safety antimicrobial activity moxifloxacin-containing regimen ( moxifloxacin , rifampin , pyrazinamide , ethambutol [ MRZE ] ) moxifloxacin substitute isoniazid , standard control regimen ( isoniazid , rifampin , pyrazinamide , ethambutol [ HRZE ] ) first two month treatment sputum smear-positive pulmonary tuberculosis . The assessment antimicrobial activity sputum culture-conversion . Higher rate sputum culture conversion 2 month treatment moxifloxacin-containing regimen would support Phase 3 clinical trial moxifloxacin treatment regimen less current 6 month standard regimens . Rationale - Current treatment smear positive pulmonary tuberculosis require minimum 6 month , treatment duration challenge patient tuberculosis control program . Therefore , high priority tuberculosis research identification agent shorten treatment . Several fluoroquinolone antibiotic potent activity Mycobacterium tuberculosis ( M. tuberculosis ) preclinical test . Of currently available fluoroquinolones , moxifloxacin excellent activity vitro animal model tuberculosis , favorable pharmacokinetic profile ( serum half-life 10-12 hour ) , lack problematic drug-drug interaction , need dosage adjustment renal hepatic insufficiency , excellent safety profile . In addition , murine model tuberculosis , substitution moxifloxacin isoniazid result significant reduction time culture conversion time sterilization compare standard combination rifampin , isoniazid pyrazinamide . However , moxifloxacin fully evaluate human tuberculosis treatment . There need assess anti-tuberculosis activity moxifloxacin-containing regimen , also safety prolong therapy moxifloxacin . Two-month culture conversion rate well-accepted surrogate marker sterilize activity anti-tuberculosis drug . Rifampin pyrazinamide , key drug current 6-month regimen , markedly increase 2-month culture-conversion rate . Therefore , study use 2-month culture conversion rate measure antimicrobial activity moxifloxacin .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Suspected pulmonary tuberculosis acidfast bacillus stain smear expectorate induced sputum . Patients whose sputum culture grow M. tuberculosis M. tuberculosis isolate resistant ( one ) isoniazid , rifampin , fluoroquinolones , discontinue study , follow 14 day detect late toxicity study therapy . Patients extrapulmonary manifestation tuberculosis , addition smearpositive pulmonary disease , eligible enrollment . Sputum must expectorate induced ; smear result respiratory secretion obtain bronchoalveolar lavage bronchial wash may use assessment study eligibility . Willingness HIV test perform , HIV serostatus know last documented negative HIV test 6 month prior enrollment . HIV test need repeat write documentation positive test ( positive ELISA Western Blot plasma HIVRNA level great 5000 copies/ml ) time past . 7 ( seven ) few day multidrug therapy tuberculosis disease 6 month precede enrollment . 7 ( seven ) few day fluoroquinolone therapy 3 month precede enrollment . Age &gt; 18 year Karnofsky score least 60 ( require occasional assistance able care his/her need ; see Appendix B ) . Signed informed consent Women childbearing potential must agree practice adequate ( barrier ) method birth control abstain heterosexual intercourse study therapy . Laboratory parameter do , &lt; 14 day prior , screen : Serum amino aspartate transferase ( AST ) activity ≤ 3 time upper limit normal Serum total bilirubin level ≤ 2.5 time upper limit normal Serum creatinine level ≤ 2 time upper limit normal Complete blood count hemoglobin level least 7.0 g/dL Complete blood count platelet count least 50,000/mm3 Serum potassium &gt; 3.5 meq/L Negative pregnancy test ( woman childbearing potential ) Breastfeeding Known intolerance study drug Known allergy fluoroquinolone antibiotic Concomitant disorder condition moxifloxacin ( MXF ) , isoniazid ( INH ) , rifampin ( RIF ) , pyrazinamide ( PZA ) , ethambutol ( EMB ) contraindicate . These include severe hepatic damage , acute liver disease cause , acute uncontrolled gouty arthritis . Current plan therapy intensive phase therapy use drug unacceptable interaction rifampin ( rifabutin substitute rifampin continuation phase therapy ) . Current plan antiretroviral therapy intensive phase therapy . History prolong QT syndrome current plan therapy quinidine , procainamide , amiodarone , sotalol , disopyramide , ziprasidone , terfenadine intensive phase therapy . Pulmonary silicosis Central nervous system TB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
	<keyword>treatment</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>